Diabetes Features

New research from Diabetes UK has found that only a small percentage of the UK public are aware of how life-changing this condition can be. Everyone needs to be aware that diabetes is a serious condition with serious consequences, which is becoming more common.

People with a severe mental illness die 15–20 years earlier than they would have done, had they not had a severe mental illness. The principle cause of this increased mortality is from long-term conditions such as diabetes, cardiovascular disease, respiratory disease and cancer. 

Patients with type 2 diabetes are at greater risk for heart disease and stroke even when glucose levels are under control. In this one-to-one interview, Professor Stephen Bain, Professor of Medicine (Diabetes) at ABM University Health Board, discusses new advances in cardiovascular and diabetes management.

A review of the latest clinical trial data and medical advances from the European Association for the Study of Diabetes 53rd Annual Meeting.

A review of the latest clinical trial data and medical advances from the European Association for the Study of Diabetes 53rd Annual Meeting.

This article is based on a presentation given by Dr Chris Smith, Consultant in Diabetes and Endocrinology, RAH and Diabetes UK Clinical Champion, at the GM Conference Ageing and Healthcare Today, held in Edinburgh.

A new class of medication, known as sodium- glucose transporter-2 (SGLT2) inhibitors, is associated with lower rates of death and hospitalisation for heart failure when used to treat patients with type 2 diabetes according to a study presented at the ADA conference.

The risk of developing type 2 diabetes by age 20 was 12 times as high in severely obese American Indian children aged five to nine years as in normal- weight youth in that age range, according to a study presented at the ADA congress.

New findings from a post-hoc analysis of the LEADER cardiovascular (CV) outcomes trial were presented recently at the 77th annual Scientific Sessions of the American Diabetes Association (ADA).

A long-acting, oral insulin tablet has been found to safely improve glycaemic control as effectively as the common, injected insulin glargine in people with type 2 diabetes according to a study presented at the ADA.